NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.86 +0.84 (+1.08%) GOLD FUTURES
2,392.90 +33.00 (+1.40%) DOW
39,850.55 +292.44 (+0.74%) Bitcoin GBP
51,987.50 +3,520.91 (+7.26%)
Cipla Limited (CIPLA.NS)
- Reuters
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports
Cipla's promoter group is looking to sell a 2.53% stake in India's third-largest drugmaker via a block deal worth 26.37 billion rupees (nearly $316 million), CNBC-TV18 reported on Tuesday, citing sources. The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said. Cipla did not immediately respond to a Reuters request for comment.
- Reuters
UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.
- Reuters
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
HYDERABAD/BENGALURU (Reuters) -Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.
